Company’s technology and Mab pipeline will add to Eisai’s anticancer small molecules.

Eisai plans to enter the biologic therapeutics field through a $325-million acquisition of Morphotek.

The company believes it can hone its focus on addressing unmet medical needs, especially those of cancer patients. Eisai expects to pad its small molecule driven oncology research program with Morphotek’s technologies and therapeutic Mabs.

Eisai plans on closing the transaction sometime during its first fiscal quarter of 2007.

Previous articleLilly Commits $50M More to Global TB Partnership
Next articleCharles River Inks deal with Shanghai BioExplorer to Form Preclinical Services Company